Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- New Dosage Added to Taxol for Gastric Cancer Treatment
March 9, 2015
- Gilead’s Sofosbuvir Likely to Get Japan Greenlight as Early as March-End
March 6, 2015
- Govt Preparing Environment to Deliver Japanese-Originated Drugs: Amari
March 6, 2015
- Aso Shrugs Off Question on Ibuki’s Annual NHI Price Revision Remarks
March 6, 2015
- Ishin Submits Bill to Optimize Clinical Research
March 5, 2015
- NCGM Opts Out of Special Mixed Care Scheme in Tokyo Economic Zone
March 5, 2015
- Orphan Drugs for More than 50,000 Patients Can Be Developed under New Scheme
March 3, 2015
- Pharma Might Skirt Market-Price Based Price Cuts in 2017 If Physician Fees Become Taxable
March 3, 2015
- MHLW Won’t Order Novartis to Revise Package Inserts over Delayed ADR Reports, Urges Firms to Inspect Safety Control Regime
March 2, 2015
- PMDA Evaluating Sitagliptin for Risk of Thrombocytopenia
March 2, 2015
- Novartis Slapped with 15 Day Biz Suspension over Flawed ADR Reporting
February 27, 2015
- PAFSC Second Committee Backs Approval of Celgene’s Pomalidomide
February 27, 2015
- Roundtable Discussion for Healthcare Policy for 2035 Kicked Off
February 27, 2015
- MHLW OKs 60 New APIs in 2014, Doubling from Year Ago
February 26, 2015
- MHLW Prods Self-Inspections at Insurance Pharmacies after Medication History Fuss
February 25, 2015
- Drug Price Settlement Rate at 76.2% in December: MHLW
February 24, 2015
- Shelved Decision on Xarelto Recommendation Doesn’t Mean Disapproval: MHLW
February 24, 2015
- New Division for Cancer and Specific Diseases Control to Handle Hepatitis Measures after Reorganization of HSB
February 24, 2015
- Editor’s Pick: Five Healthcare News Headlines for Feb. 9 - 22
February 23, 2015
- Shiozaki Says Annual NHI Price Cuts Could Hit Distributors, Mar Innovation Drive; Ministry to Consider Plan based on Govt’s Economic Blueprint
February 23, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…